Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Inborn Errors of Metabolism

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Protein Import into the Peroxisomes

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Novel Variant in an Israeli Bedouin Family: The First Reported Cases of Carbonic Anhydrase VA (CA5A) Deficiency in Israel.

Genes·2026

Same author

Pharmacotherapies for Gaucher disease: what's new on the horizon?

Expert opinion on pharmacotherapy·2026

Same author

New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment.

The Lancet. Neurology·2026

Same author

2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C.

Journal of inherited metabolic disease·2026

Same author

Immunological Manifestations in GALE Deficiency: Extending the Spectrum Beyond Thrombocytopenia and Galactosemia.

Journal of clinical immunology·2026

Same author

Pyruvate Dehydrogenase Complex Deficiency: A Review of Treatments and Case Series.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Lysosomal storage disorders in the newborn.

Orna Staretz-Chacham¹, Tess C Lang, Mary E LaMarca

¹Office of the Clinical Director, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 35, Room 1A213, 35 Convent Dr, MSC 3708, Bethesda, MD 20892-3708, USA.

|April 2, 2009

Summary

Lysosomal storage disorders (LSDs) can appear in newborns, yet are often overlooked. Early recognition of specific symptoms is crucial for timely diagnosis and treatment of these rare metabolic diseases.

More Related Videos

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

Quantification of Endosome and Lysosome Motilities in Cultured Neurons Using Fluorescent Probes

Quantification of Endosome and Lysosome Motilities in Cultured Neurons Using Fluorescent Probes

Published on: May 22, 2017

Related Experiment Videos

Last Updated: Jun 24, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

Quantification of Endosome and Lysosome Motilities in Cultured Neurons Using Fluorescent Probes

Quantification of Endosome and Lysosome Motilities in Cultured Neurons Using Fluorescent Probes

Published on: May 22, 2017

Area of Science:

Biochemistry
Genetics
Pediatrics

Background:

Lysosomal storage disorders (LSDs) are rare genetic metabolic diseases.
They affect approximately 1 in 1500 to 7000 live births.
LSDs are often not considered in the initial evaluation of sick newborns.

Purpose of the Study:

To review the early clinical features of LSDs presenting in the neonatal period.
To highlight diagnostic tests and treatment options for infantile LSDs.
To increase physician awareness of LSDs in newborns to reduce misdiagnosis.

Main Methods:

Literature review focusing on perinatal phenotypes of LSDs.
Analysis of early clinical manifestations including neurological, respiratory, endocrine, and cardiovascular symptoms.
Examination of dysmorphic features, hepatosplenomegaly, skin/ocular involvement, and hydrops fetalis.

Main Results:

Over 50 types of LSDs exist, with many manifesting neonatally.
Specific perinatal symptoms include neurological deficits, respiratory distress, organomegaly, and congenital anomalies.
Early detection is vital as prompt therapy improves outcomes for several LSDs.

Conclusions:

LSDs should be included in the differential diagnosis for various perinatal conditions.
Increased awareness of neonatal LSD presentations can lead to earlier detection and intervention.
Timely management is critical for improving prognosis in affected newborns.